The University of Chicago Header Logo

Connection

Mark Kozloff to Cetuximab

Back to Details
This is a "connection" page, showing publications Mark Kozloff has written about Cetuximab.
Mark Kozloff
Connection Strength
0.028
Cetuximab
  1. Evaluation of a novel rash scale and a serum proteomic predictor in a randomized phase II trial of sequential or concurrent cetuximab and pemetrexed in previously treated non-small cell lung cancer. BMC Cancer. 2014 Jan 04; 14:5.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.